Mount Sinai School of Medicine  
Institutional Biosafety Committee  

November 18, 2010

Present: Drs. Wetmur, Bishop, Simon, tenOever; Ms. Erlitz (by teleconference),  
Mr. Hauck, Ms. Meseck.

Also Present: Mr. Maglione, Ms. Schneier.

1) Approval of Minutes  
   a. Upon motion duly made and seconded, the minutes of the May 20, 2010 meeting  
      were unanimously approved.

2) Protocols  
   a. Unanimous approval was given for the following studies:
      i. GCO #08-0844 (Jill Kalman) A Phase I Trial of Intracoronary Administration  
         of MYDICAR in Subjects with Heart Failure Divided into Two Stages: Stage  
         One Open-Label, Sequential Dose-Escalation Cohorts and in Stage Two by  
         Randomized, Double-Blind, Placebo-Control, Parallel Cohorts – renewal –  
         initial approval given in 2008 and renewal given in 2009.
      ii. GCO #05-1362(2) (Natalie Pica) Development of a Guinea Pig Model of  
           Metapneumovirus Transmission – approved at BSL-2.
      iii. GCO #??.-???? (Benjamin tenOever) Artificial RNA Viral Design Through  
           Synthetic Biology - approved at BSL-2.

3) Reduction in Biocontainment Level for Novel H1N1 Influenza A Viruses  
   a. It was agreed that the biocontainment level for novel H1N1 can be lowered to BSL-2.

4) New Members  
   a. Dr. Morrison will be contacted regarding appointing new members to the committee.

5) IRB Link to IBC  
   a. Dr. Silverstein will be contacted regarding creating a link in InfoEd from the IRB  
      page to IBC to ensure renewals are automatically communicated to the IBC.